Sign in
Companies / MRK vs REGN

MRK vs REGN: Merck and Regeneron Pharmaceuticals

Pharmaceuticals and Biotechnology
Compare more companies

Merck (MRK) reported $65.0B in revenue against a 28.1% net margin, while Regeneron Pharmaceuticals (REGN) reported $14.3B at a 31.4% net margin, most recently.

MetricMRKREGN
Revenue$65.0B$14.3B
Net Income$18.3B$4.5B
Gross Margin74.8%—
Operating Margin—24.9%
EPS (Diluted)$7.28$41.48
Free Cash Flow$12.4B$4.1B
Total Debt$49.3B$2.7B
P/E Ratio14.5×18.6×
P/B Ration/mn/m
Stock Price$147.90$910.75
Free: last 5 years
Fiscal yearFY2008 🔒FY2009 🔒FY2010 🔒FY2011 🔒FY2012 🔒FY2013 🔒FY2014 🔒FY2015 🔒FY2016 🔒FY2017 🔒FY2018 🔒FY2019 🔒FY2020 🔒FY2021FY2022FY2023FY2024FY2025
MRK Revenue•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$48.7B$59.3B$60.1B$64.2B$65.0B
REGN Revenue•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$16.1B$12.2B$13.1B$14.2B$14.3B

More on MRK

More on REGN

Other comparisons